3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
9
Small Cell Lung Carcinoma
6
Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms by Site
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Gallbladder Neoplasms
2
Bile Duct Neoplasms
2
Vaccinia
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Resectable Intrahepatic Cholangiocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Interventions
Specimen Handling
3
fludarabine
2
aldesleukin
2
Sunitinib
2
Fluorouracil
2
Cyclophosphamide
2
Bevacizumab
2
trastuzumab deruxtecan
1
sodium propionate
1
semaglutide
1
repotrectinib
1
patritumab deruxtecan
1
isosorbide-5-mononitrate
1
fludarabine phosphate
1
dehydroftorafur
1
Tomography, X-Ray Computed
1
Radiosurgery
1
Positron-Emission Tomography
1
Photography
1
Pemetrexed
1
Pafolacianine
1
Memantine
1
Magnetic Resonance Spectroscopy
1
Magnetic Resonance Imaging
1
Leucovorin
1
Isosorbide
1
Irinotecan
1
Interleukin-2
1
IDRX-42
1
High-Intensity Interval Training
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
durvalumab
×
30 days
×
Clear all
No trials found.